ZEISS releases new live cell imaging platform

ZEISS has introduced a microscopy system called ZEISS Celldiscoverer 7, the latest technology for live cell imaging by the Germany-based imaging company.  

Celldiscoverer 7 combines the features of a boxed microscope with the image quality and flexibility of a classic inverted research microscope.  

"In contrast to other boxed microscopes with limited flexibility, ZEISS Celldiscoverer 7 can be adapted to a whole range of tasks and applications," according to the ZEISS press release.  

In particular, the Celldiscoverer 7 allows scientists to choose from a selected range of microscope cameras in order to tailor to the needs of their own research labs. Design features include a hardware-based autofocus, which sustains a crisp automatic focus of samples and simultaneously detects sample thickness and optical properties.  

The ZEN 2.3 imaging software package in the Celldiscoverer 7 provides additional features including the new ZEISS Axiocam 512 mono microscope camera with a 12 MP resolution and a large field of view allows fluorescence screening applications with high throughput, automation wizards, large-data acquisition and data processing in 2D and 3D. Scientists will also be able to securley export data to a third-party image analysis software.  

"The new optical design of ZEISS Celldiscoverer 7 together with advanced automatic calibration routines helps researchers to achieve reproducible high-quality data even from complex long-term, time-lapse imaging experiments," acording to the press release. "The newly developed optics of ZEISS Celldiscoverer 7 in combination with rapid GPU-based deconvolution algorithms allow scientists to extract a maximum of information from their samples, artifact-free and in the shortest time possible." 

""

A recent graduate from Dominican University (IL) with a bachelor’s in journalism, Melissa joined TriMed’s Chicago team in 2017 covering all aspects of health imaging. She’s a fan of singing and playing guitar, elephants, a good cup of tea, and her golden retriever Cooper.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”